Clinical Trial Update: A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

The trial PRISM evaluating preoperative irradiation with tremelimumab and ongoing durvalumab for resectable/advanced hepatocellular carcinoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: WITHDRAWN